Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma

Sean O’Quinn, Xiao Xu, Ian Hirsch AstraZeneca, Gaithersburg, MD, USA Background: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha–dire...

Full description

Bibliographic Details
Main Authors: O'Quinn S, Xu X, Hirsch I
Format: Article
Language:English
Published: Dove Medical Press 2019-01-01
Series:Journal of Asthma and Allergy
Subjects:
Online Access:https://www.dovepress.com/daily-patient-reported-health-status-assessment-improvements-with-benr-peer-reviewed-article-JAA

Similar Items